bHLHa17, Class A basic helix-loop-helix protein 17, SCL antibody, Stem cell protein, T cell acute lymphocytic leukemia 1, T cell acute lymphocytic leukemia 1 protein, T cell leukemia/lymphoma 5 protein, T-cell acute lymphocytic leukemia protein 1, T-cell leukemia/lymphoma protein 5, Tal 1, Tal 1 product, TAL 1 protein, TAL-1, tal1, TAL1_HUMAN, TCL 5, TCL5.
Activation of TAL1 characterizes up to 60% of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.
Klonalität:
Polyclonal
Konzentration:
1ug/ul
Puffer:
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Quelle:
KLH conjugated synthetic peptide derived from human Tal1
Target-Kategorie:
Tal1
Application Verdünnung:
IF(IF=1:50-200)
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
